No Data
Youcare Pharmaceutical Gets Approval to Conduct Clinical Trial for High Cholesterol Treatment
youcare pharmaceutical group (688658.SH): Subsidiary YKYY015 injection obtained clinical trial approval from the National Medical Products Administration.
Glory 31st October | youcare pharmaceutical group (688658.SH) announced that its wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration ("NMPA") for YKYY015 injection to treat primary hypercholesterolemia (both familial and non-familial) or diversified bond hyperlipidemia patients characterized by elevated LDL-C, and the company will carry out Phase I clinical trials of this product.
Youcare Pharmaceutical Group (688658): Bright performance growth in Q3 2024, steady progress in innovative pipeline listing process.
2024Q3 single-quarter performance growth outstanding, turning losses into profits, maintaining a "buy" rating. In 2024Q1-Q3, the company achieved revenue of 2.992 billion yuan (+1.15% year-on-year, all figures below are on a year-on-year basis), net profit attributable to shareholders.
Youcare Pharmaceutical Group (688658): Significant progress in heavyweight products, the small nucleic acid platform is worth looking forward to.
Key investment points: Event: On the evening of October 30, 2024, the company released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 2.992 billion yuan (+1.15% year-on-year); achieved net profit attributable to the parent company.
Yuekang Pharmaceutical: Third Quarter Report 2024
Third Quarter Report 2024
No Data
No Data